GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (XTER:PV3) » Definitions » Net Interest Income (for Banks)

EyePoint Pharmaceuticals (XTER:PV3) Net Interest Income (for Banks)


View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


EyePoint Pharmaceuticals (XTER:PV3) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.